

How to cite this article:

Vázquez-Blanco S, González-Freire L, Dávila-Pousa MC, Crespo-Diz C.
pH determination as a quality standard for the elaboration of oral liquid
compounding formula. Farm Hosp. 2018;42(6):221-227.



ORIGINALS

Bilingual edition English/Spanish

pH determination as a quality standard for the elaboration of oral liquid compounding formula

Determinación del pH como criterio de calidad en la elaboración de fórmulas magistrales orales líquidas

Silvia Vázquez-Blanco, Lara González-Freire, María Carmen Dávila-Pousa, Carlos Crespo-Diz

Pharmacy Unit. Complejo Hospitalario Universitario de Pontevedra, Pontevedra. Spain.

Author of correspondence

Silvia Vázquez-Blanco
Servicio de Farmacia
Complejo Hospitalario Universitario
de Pontevedra.
Avenida Mourente s/n
36071 Pontevedra, España.

Email:
silviavazquezblanco@gmail.com

Recibido el 5 de noviembre de 2017;
aceptado el 30 de junio de 2018.

DOI: 10.7399/fh.10932

Abstract

Objective: pH is a critical factor for all those medications prepared as aqueous liquid forms, because it has an impact on the solubility of the molecule, determining the stability of medications, the biological tolerability of the formulation, and the activity of the molecule. The objective of this study is to determine the optimum pH range for the oral liquid formulations more frequently prepared at the Pharmacy Unit, in order to standardize and incorporate said value into the standard protocols of action as a quality control criterion.

Method: The study was conducted in three stages. The first stage consisted in a retrospective study of the records of preparation of those oral liquid formulations prepared at least 5 times since January, 2015 to December, 2016, in our Pharmacy Unit; the main value and standard deviation of the pH values recorded for each formulation were calculated. In a second stage, there was a bibliographic search in order to understand the pH for the maximum stability of the molecule, and to confirm if this characteristic was recorded as a requirement for quality control in the procedures described in the formulation guidelines. In the third stage, it was confirmed if the pH values determined coincided with the maximum stability pH described in literature, and acceptance ranges were established.

Results: In total, 31 formulations were reviewed (14 solutions / 17 suspensions). The maximum stability pH value was known for 19 (61.3%) of the molecules and/or oral liquid formulations evaluated; 15 (78.9%) of these were within this range, and the remaining 4 (21.1%) presented a standard deviation of ± 0.5 regarding the pH value referenced in the bibliography. The pH range for the same standard work procedure ranged between 0.32 and 1.51. An acceptance pH range of ± 0.75 was determined as quality control.

Resumen

Objetivo: El pH es un factor crítico para todos aquellos medicamentos que se encuentran en formas líquidas acuosas, ya que puede ejercer un efecto sobre la solubilidad del principio activo condicionando la estabilidad de los medicamentos, la tolerancia biológica de la forma farmacéutica y la actividad del principio activo. El objetivo de este trabajo es establecer el rango óptimo de pH de las fórmulas orales líquidas más frecuentemente elaboradas en el Servicio de Farmacia para estandarizar e incorporar dicho valor en los protocolos normalizados de trabajo como criterio de control de calidad.

Método: El estudio se desarrolló en tres fases. En una primera fase se realizó un estudio retrospectivo de los registros de elaboración de las fórmulas orales líquidas elaboradas, al menos 5 veces, desde enero de 2015 a diciembre de 2016 en nuestro Servicio de Farmacia, y se calculó el valor medio y la desviación estándar de los valores de pH registrados para cada fórmula. En una segunda fase se realizó una búsqueda bibliográfica para conocer el pH de máxima estabilidad del principio activo y comprobar si esta característica se registra como requisito de control de calidad en los procedimientos descritos en los formularios de referencia. En una tercera fase se comprobó si los pH determinados se correspondían con el de máxima estabilidad descrito en la literatura y se establecieron rangos de aceptación.

Resultados: Se revisaron un total de 31 fórmulas (14 soluciones/17 suspensiones). Se conocía el valor del pH de máxima estabilidad de 19 (61,3%) de los principios activos y/o fórmulas orales líquidas evaluadas, de las cuales 15 (78,9%) se encontraban dentro del mismo y las 4 restantes (21,1%) presentaron una desviación estándar de $\pm 0,5$ con respecto al valor de pH referenciado en la bibliografía. El rango de pH para un mismo procedimiento normalizado de trabajo oscilaba entre 0,32 y 1,51. Se estableció como control de calidad un rango de aceptación de pH de $\pm 0,75$.

KEYWORDS

Drug compounding; Drug stability; pH; Quality control; Quality indicator; Pharmaceutical formulary.

PALABRAS CLAVE

Control de calidad; Estabilidad; Formulación magistral; Formularios; Indicador de calidad; pH.



Los artículos publicados en esta revista se distribuyen con la licencia
Articles published in this journal are licensed with a
Creative Commons Attribution 4.0
<https://creativecommons.org/licenses/by-nc-nd/4.0/>
La revista Farmacia no cobra tasas por el envío de trabajos,
ni tampoco por la publicación de sus artículos.

Conclusions: An optimal pH range has been determined for the 31 oral liquid formulations more widely prescribed in our hospital. This characteristic should be part of the galenic validation for these preparations, as well as of its routine quality control, in order to ensure their quality and efficacy.

Introduction

The pH of an aqueous solution is a critical factor to be considered for all those medications prepared in aqueous liquid forms. The potential effect of pH on solubility will be a decisive factor for the stability of the medications to be administered. Moreover, the biological tolerability of the formulation can be compromised, as well as the activity of the active principle (AP).

The solubility of acid and basic drugs is pH-dependent, and based on its ionization constant, which creates a balance between the ionized and non-ionized species, and leads to the dilution of the acid and/or the base. Aqueous reactions are generally catalyzed by pH. There have been studies measuring the degradation rates at different pH values, keeping constant the temperature, ionic strength, and concentration of the solvent. The conclusion of these studies was that, if pH is not within a maximum stability range, the non-ionized form of the drug will prevail, leading to the creation of insoluble precipitates².

Each AP has a pH range for its maximum stability, and it can lose activity outside this range, due to physical and chemical transformations. The combination with diluents, excipients, and other medications with a different pH, can trigger undesired effects and compromise the stability of the formulation. It has been confirmed that, for example, folic acid and furosemide will precipitate at a pH below 8 and 7, respectively; omeprazole is degraded at pH values below 7.8; propranolol breaks down if exposed to alkaline pH values, and captopril experiences oxidative degradation in means presenting pH values above 4³.

Therefore, pH determination is important for the preparation of oral liquid formulations (OLFs), because it affects the solubility, activity, absorption, biological tolerability and stability of the AP^{4,5}.

However, most formulation guidelines with acknowledged prestige about OLFs for pediatric patients, such as: "Formulación Pediátrica Manuela Atienza", "Standardised formulations for New Zealand", "Nationwide Children's Hospital", "Hospital for Sick Children" and "University of Michigan College of Pharmacy", do not include any pH values for maximum stability of the preparations described. On the other hand, the Spanish National Formulary (FNE) includes in its procedure No. PN/L/CP7001/00 the determination of pH as quality control for solutions, suspensions and syrups, but exclusively for formulations prepared in lots⁶⁻¹¹.

Given the lack of compatibility data between OLF components, we hereby state that knowing the pH values for maximum stability of the medications to be administered is a predictive factor that can prevent serious stability problems, and that its determination will ensure the quality and efficacy of the formulations prepared.

The objective of this study is to determine the optimal pH range for the OLFs more frequently prepared at the Hospital Pharmacy Unit (HPU), in order to standardize and incorporate said value into the standard work procedures (SWPs) as a quality control criterion.

Methods

1. A retrospective study was conducted on the preparation records of all OLFs prepared at the HPU from January, 2015 to December, 2016. Those OLFs prepared with a ≥ 5 frequency were selected, and the pH values evaluated were collected. Mean value and standard deviation were calculated for each preparation, as well as the range, obtained through the difference between the maximum and minimum values recorded. These pH determinations were conducted with a sensION™ pH31 meter®.
2. In order to determine the maximum stability pH of the AP, the following bibliographic sources were reviewed: the product specifications of the molecules by our main provider (www.acofarma.com/es/formulacion-magistral/fichas-tecnicas) and the books: Trissel's "Stability of Compounded Formulations" 2nd edition, and "Handbook of Extemporaneous Preparation" (2010), as well as the product specifications by the Spanish Agency of Medicines and Medical Devices (AEMPS) for

Conclusiones: Se ha establecido un rango óptimo de pH para las 31 fórmulas orales líquidas de mayor prescripción en nuestro hospital. Esta característica debería formar parte de la validación galénica de estas preparaciones, así como de su control de calidad rutinario, para asegurar la calidad y eficacia de las mismas.

branded medications to be administered intravenously as solution, and the United States Pharmacopeia 32th edition and National Formulary 27th edition (USP 32- NF 27)^{12,16}.

The most relevant pediatric formulation guidelines previously mentioned were also consulted⁶⁻¹⁰.

3. Finally, the pH values recorded were compared with the maximum stability values stated in the bibliography, and an acceptance range was determined for each of the OLFs evaluated.

Results

In total, 31 OLFs were reviewed according to the criteria of the first stage of the study: 14 solutions and 17 suspensions (Table 1). For all OLFs prepared during the period of the study, and which met the inclusion criteria, the following data were collected: pH mean value, standard deviation, and pH ranges for the same SWP (Table 2). The latter value ranged between 0.32 and 1.51.

After consulting the different bibliographical sources in order to find the maximum stability pH of the AP, only the value of the 19 (61.3 %) of the APs and/or OLFs evaluated was available.

Regarding the formulation guidelines consulted, a pH value as quality control was determined for 3 (9.7%) of the OLFs selected in the "Formulación Pediátrica Manuela Atienza"; 10 (32.3%), in the "Standardised formulations for New Zealand", 1 (3.2%) in the "Nationwide Children's Hospital", 1 (3.2%) in the "University of Michigan College of Pharmacy", and none in the "Hospital for Sick Children".

The data on maximum stability pH for APs and OLFs referenced in the bibliography selected appear in Table 3.

Of those 19 OLFs and/or PAs with a known pH range for maximum stability, 15 (78.9%) were within said range, and the remaining 4 (21.1%) presented a ± 0.5 standard deviation.

Based on the data collected in the bibliography consulted, and the variability of the determinations evaluated, it was determined to include pH as regular quality control for SWPs with a ± 0.75 acceptance range.

Discussion

The pH is one of the factors with higher impact on the stability of a formulation in aqueous solution. Knowing the maximum stability pH for an AP of OLFs is essential to guarantee the quality of the preparation; it must remain stable during all the validity and preservation period established¹.

In most of the formulation guidelines reviewed, pH is not included either as a control to be conducted or an acceptance range; a pH range for each monograph is only described in USP 32- NF 27. In the FNE, pH determination (PN/L/CP/001/00) is included as a product control procedure, and it is compulsory for all solutions, suspensions, syrups and gels prepared in lots^{11,16}.

It is worth highlighting that there is limited bibliography providing data on the pH values for maximum stability of an AP and/or OLF.

Given that there are many medications, such as furosemide, propranolol, omeprazole and captopril, with an already known and well defined pH for maximum stability, and the formulation is not stable unless within it, we consider that this is a value that must be known and evaluated, even for individualized formulations not prepared in lots⁵. The SWP established should include this criterion.

For those OLFs with unknown maximum stability pH range, or insoluble AP, pH determination is still a quality indicator, because it must stay stable and reproducible for the same SWP, as has been demonstrated in the study.

Even though the HPU evaluated and recorded pH routinely for all individual OLFs, there was no acceptance range established for each SWP. This study has been useful in order to include this criterion in the protocol, and its evaluation as quality control.

Table 1. Formulation and composition of the OLFs prepared at the HPU

PREPARATION	FORMULATION	COMPOSITION
Acetazolamide 25 mg/mL	Suspension	Acetazolamide 250 mg tablet 10 tablets Citric acid monohydrate 800 mg Glycerin q.s. Sterile water 30 mL Acofarma plain syrup q.s. for 100 mL
Amlodipine 1 mg/mL	Suspension	Amlodipine 10 mg tablet 10 tablets Sterile water 5 mL Methylcellulose 1% oral gel 50 mL Acofarma plain syrup q.s. 100 mL
Captopril 1 mg/mL	Solution	Captopril 100 mg EDTA disodium salt 30 mg Vitamin C 500 mg Sterile water q.s. for 100 mL
Cefuroxime 50 mg/mL	Suspension	Cefuroxime 500 mg tablet 10 tablets Glycerin q.s. Strawberry flavoring 0.1 mL Acofarma plain syrup q.s. for 100 mL
Clobazam 2.5 mg/mL	Suspension	Clobazam 10 mg tablet 25 tablets Glycerin 5 g Sodium saccharine 400 mg Liquid sorbitol 70% 30 mL Carboxymethyl cellulose 1% oral gel q.s. for 100 mL
Clonidine 0.1 mg/mL	Suspension	Clonidine 0.15 mg tablet 40 tablets Sterile water 10 mL Acofarma plain syrup q.s. for 60 mL
Desmopressin 1.33 µg/mL	Solution	Desmopressin amp 4 µg/mL 50 mL Glucose 5% q.s. 150 mL
Dipyridamole 10 mg/mL	Suspension	Dipyridamole 100 mg tablet 10 tablets Glycerin q.s. Citric acid monohydrate 300 mg Sterile water 5 mL Acofarma plain syrup q.s. for 100 mL
Ethambutol 100 mg/mL	Solution	Ethambutol hydrochloride 5,000 mg Citric acid monohydrate 300 mg Sterile water 30 mL Acofarma plain syrup q.s. 100 mL
Ethosuximide 50 mg/mL	Solution	Ethosuximide 250 mg caps 20 caps Sodium citrate dihydrate 250 mg Sodium saccharine 150 mg Glycerin 12.5 mg Sterile water 20 mL Acofarma plain syrup q.s. for 100 mL
Flecainide 10 mg/mL	Solution	Flecainide acetate 1,000 mg Sterile water 50 mL Acofarma plain syrup q.s. for 100 mL
Fludrocortisone 20 µg/mL	Suspension	Fludrocortisone 0.1 mg tablet 20 tablets Citric acid monohydrate 600 mg Ethanol 99% 0.5 mL Acofarma plain syrup 10 mL Lemon essence 0.1 mL Methylcellulose 1% oral gel q.s. for 100 mL
Folic acid 2.5 mg/mL	Solution	Folic acid 250 mg Nipagin sodium 100 mg Sodium hydroxide 1N q.s. Sterile water q.s. for 100 mL
Furosemide 4 mg/mL	Solution	Furosemide 250 mg/25 mL amp 40 mL Sodium saccharine 100 mg Preservative water q.s. for 100 mL

Table 1 (cont.). Formulation and composition of the OLFs prepared at the HPU

PREPARATION	FORMULATION	COMPOSITION
Gabapentin 50 mg/mL	Solution	Gabapentin 5,000 mg Sodium saccharine 100 mg Carboxymethyl cellulose 1% oral gel 50 mL Strawberry flavoring 0,1 mL Acofarma plain syrup q.s. for 100 mL
Griseofulvin 50 mg/mL	Suspension	Griseofulvin 5,000 mg Glycerin 5,000 mg Sodium saccharine 200 mg Sterile water 60 mL Peach essence 0.1 mL Sodium hydroxide 1N 0.05 mL Methylcellulose 1% oral gel q.s. for 100 mL
Hydrocortisone 2.5 mg/mL	Suspension	Hydrocortisone 250 mg Glycerin 1 mL Citric acid monohydrate 600 mg Plain syrup 10 mL Sterile water 10 mL Methylcellulose 1% oral gel q.s. for 100 mL
Isoniazid 50 mg/mL	Solution	Isoniazid 5,000 mg Preservative water 50 mL Liquid sorbitol 70% 50 mL
Ketamine 10 mg/mL	Solution	Ketamine 50 mg/mL vial 20 mL Acofarma plain syrup 40 mL Lemmon essence 0.1 mL Sterile water q.s. for 100 mL
Lamotrigine 10 mg/mL	Suspension	Lamotrigine 100 mg tablet 10 tablets Sterile water 5 mL Strawberry flavoring 0.1 mL Acofarma plain syrup q.s. for 100 mL
Levodopa-Carbidopa 5-1.25 mg/mL	Suspension	Levodopa/carbidopa 25/100 mg tablet 5 tablets Citric acid monohydrate 200 mg Sterile water 25 mL Carboxymethyl cellulose 1% oral gel 25 mL Acofarma plain syrup q.s. for 100 mL
Levothyroxine 25 µg/mL	Suspension	Levothyroxine 100 µg tablet 24 tablets Levothyroxine 50 µg tablet 2 tablets Sterile water 20 mL Acofarma plain syrup q.s. for 100 mL
Midazolam 1 mg/mL	Solution	Midazolam 15 mg/3 mL amp 12 mL Citric acid 400 mg Acofarma plain syrup q.s. for 60 mL
Omeprazole 2 mg/mL	Solution	Sodium omeprazole 200 mg Sterile water q.s. for 100 mL
Phenobarbital 10 mg/mL	Suspension	Phenobarbital 0.1 mg tablet 10 tablets Glycerin q.s. Sodium hydroxide 1N q.s. Acofarma plain syrup 50 mL Sterile water q.s. for 100 mL
Propranolol 1 mg/mL	Solution	Propranolol clorhydrate 100 mg Citric acid monohydrae 1,000 mg Plain syrup 40 mL Sterile water 60 mL
Ranitidine 10 mg/mL	Solution	Ranitidine clorhydrate 110 mg Preservative water 50 mL Acofarma plain syrup q.s. 100 mL
Spirolactone 5 mg/mL	Suspension	Spirolactone 100 mg tablet 5 tablets Sterile water 5 mL Acofarma plain syrup q.s. for 100 mL

Table 1 (cont.). Formulation and composition of the OLFs prepared at the HPU

PREPARATION	FORMULATION	COMPOSITION
Topiramate 10 mg/mL	Suspension	Topiramate 1,000 mg
		Sterile water 10 mL
		Carboxymethyl cellulose 1% oral gel 40 mL
		Acofarma plain syrup q.s. for 100 mL
Ursodeoxycholic acid 30 mg/mL	Suspension	Ursodeoxycholic acid 300 mg caps 10 caps
		Glycerin q.s.
		Acofarma plain syrup q.s. for 100 mL
Zonisamide 10 mg/mL	Suspension	Zonisamide 100 mg caps 10 caps
		Sterile water 10 mL
		Strawberry flavoring 0,1 mL
		Acofarma plain syrup q.s. for 100 mL

amp: ampoules; caps: capsules; q.s. for: quantity sufficient for; q.s.: quantity sufficient.

Table 2. pH mean value, standard deviation and range for each compound preparation

Formulation	No. of samples	Ph mean value	Standard deviation	Range
Acetazolamide 25 mg/mL	5	5.54	0.46	0.95 (5.05-6.00)
Amlodipine 1 mg/mL	13	5.69	0.15	0.60 (5.42-6.03)
Captopril 1 mg/mL	11	3.08	0.93	0.32 (2.85-3.21)
Cefuroxime 50 mg/mL	5	5.51	0.15	0.35 (5.39-5.74)
Clobazam 2.5 mg/mL	20	6.79	0.19	0.73 (6.38-7.11)
Clonidine 0.1 mg/mL	12	5.60	0.15	0.53 (5.37-5.90)
Desmopressin 1.33 µg/mL	20	4.37	0.14	0.44 (4.13-4.57)
Dipyridamole 10 mg/mL	6	4.71	0.27	0.74 (4.18-4.92)
Ethambutol 100 mg/mL	5	2.71	0.15	0.36 (2.62-2.98)
Ethosuximide 50 mg/mL	8	5.91	0.17	0.49 (5.70-6.19)
Flecainide 10 mg/mL	20	5.62	0.22	0.86 (5.30-6.16)
Fludrocortisone 20 mg/mL	20	3.17	0.23	0.84 (2.83-3.67)
Folic acid 2.5 mg/mL	20	8.62	0.18	0.71 (8.29-9.00)
Furosemide 4 mg/mL	18	9.21	0.32	0.92 (8.64-9.56)
Gabapentin 50 mg/mL	11	6.09	0.21	0.67 (5.85-6.52)
Griseofulvin 50 mg/mL	20	6.13	0.51	1.51 (5.51-7.02)
Hydrocortisone 2.5 mg/mL	20	3.07	0.11	0.53 (2.89-3.42)
Isoniazid 50 mg/mL	20	6.48	0.23	0.88 (6.09-6.97)
Ketamine 10 mg/mL	20	5.45	0.12	0.60 (5.14-5.74)
Lamotrigine 10 mg/mL	16	5.77	0.22	0.79 (5.49-6.28)
Levodopa-carbidopa 5-1.25 mg/mL	18	4.83	0.24	1.08 (4.02-5.10)
Levothyroxine 25 µg/mL	20	5.68	0.21	0.92 (5.06-5.98)
Midazolam 1 mg/mL	16	4.21	0.14	0.50 (4.00-4.50)
Omeprazole 2 mg/mL	20	10.88	0.29	1.15 (10.11-11.26)
Phenobarbital 10 mg/mL	15	8.59	0.25	0.85 (8.15-9.00)
Propranolol 1 mg/mL	20	3.48	0.21	0.79 (2.98-3.77)
Ranitidine 10 mg/mL	14	5.54	0.11	0.40 (5.28-5.68)
Spironolactone 5 mg/mL	20	5.15	0.17	0.66 (4.86-5.52)
Topiramate 10 mg/mL	15	5.75	0.21	0.65 (5.49-6.14)
Ursodeoxycholic acid 30 mg/mL	20	5.69	0.15	0.51 (5.49-6.00)
Zonisamide 10 mg/mL	11	5.87	0.35	1.15 (5.35-6.50)

Table 3. Maximum stability pH values for the active principle and pH values of the oral liquid formulations described in the bibliography reviewed

Formulation	Maximum stability pH for the AP	pH of the OLF
Acetazolamide 25 mg/mL	4-5 ¹²	4-5 ^{7,16}
Amlodipine 1 mg/mL	NC	NC
Captopril 1 mg/mL	< 3.5 ¹²	3.8-4.3 ¹⁶
Cefuroxime 50 mg/mL	5-7.5 ¹³	3.5-7 ^{7,16}
Clobazam 2.5 mg/mL	NC	NC
Clonidine 0.1 mg/mL	4-5.5 ¹²	NC
Desmopressin 1.33 µg/mL	NC	NC
Dipyridamole 10 mg/mL	< 3.3 ¹³	3.4-4.8 ^{7,16}
Ethambutol 100 mg/mL	NC	NC
Ethosuximide 50 mg/mL	NC	3.8-4.3 ¹⁶
Flecainide 10 mg/mL	NC	NC
Fludrocortisone 20 µg/mL	NC	NC
Folic acid 2.5 mg/mL	8-9 ¹²	8-8.5 ^{10,7}
Furosemide 4 mg/mL	9 ¹²	8-9 ⁷ 7-10 ¹⁶
Gabapentin 50 mg/mL	NC	6.5-8 ¹⁶
Griseofulvin 50 mg/mL	5.5-7.5 ¹²	5.5-7.5 ¹⁶
Hydrocortisone 2.5 mg/mL	3.4-4.5 ¹²	3.5 ⁷
Isoniazid 50 mg/mL	6-7 ¹²	6-7 ⁷
Ketamine 10 mg/mL	3.5-5.5 ¹²	3.5-4.1 ¹⁶
Lamotrigine 10 mg/mL	NC	NC
Levodopa-carbidopa 5-1.25 mg/mL	4.5-7 ¹³	NC
Levothyroxine 25 µg/mL	NC	NC
Midazolam 1 mg/mL	NC	< 4.2 [2.9-3.7] ^{7,15,16}
Omeprazole 2 mg/mL	NC	9-10 ⁹
Phenobarbital 10 mg/mL	NC	> 8.5 ⁸
Propranolol 1 mg/mL	3 ¹²	2.8-3.5 ^{8,7}
Ranitidine 10 mg/mL	4.5-6 ¹³	6.7-7.5 ^{7,16}
Spironolactone 5 mg/mL	NC	NC
Topiramate 10 mg/mL	NC	NC
Ursodeoxycholic acid 30 mg/mL	NC	NC
Zonisamide 10 mg/mL	NC	NC

AP: active principle; OLFs: oral liquid formulations; UNKN: unknown.

Knowing the maximum stability pH in the preparation of an OLF, and determining an acceptance range as quality control, are indispensable requirements for an adequate galenic validation, and to guarantee treatment efficacy.

Funding

No funding.

Conflict of interests

No conflict of interests.

Bibliography

1. Loyd V, Allen Jr, Edmon OK. pH and Solubility, Stability and Absorption Part II. Science and Technology. 2011;1(8) [consultado 25/1/2017]. Disponible en: https://compoundingtoday.com/Newsletter/Science_and_Tech_1112.cfm

Contribution to scientific literature

The majority of pediatric formulation guidelines do not include pH determination as quality control for the preparation of oral liquid formulations.

The bibliographic search conducted in this study shows the impact of pH in the stability of these preparations, and the importance of knowing the pH range for maximum stability of the molecule. Being able to determine said value as quality control will allow us to guarantee the reproducibility of the same standard work procedure, and a correct galenic validation of the formulation prepared.

2. Veiga Ochoa MD, Gil Alegre ME, Torrado Durán J. Preformulación. En: Vila Jato JL, editor. Tecnología Farmacéutica Volumen I: Aspectos fundamentales de los sistemas farmacéuticos y operaciones básicas. Madrid: Síntesis; 2001; p. 27-73.

3. Allen LV. Preservatives, Antioxidants and pH. *Secundum Artem*. 2014;18(1):1-8 [consultado 25/1/2017]. Disponible en: <https://www.perrigo.com/business/pdfs/Sec%20Artem%2018.1.pdf>
4. García Palomo M, Cañete Ramírez C. Vehículos en formulaciones orales líquidas para pacientes pediátricos preparaciones estériles. *Boletín de Farmacotecnia*. 2014;4(3):1-7 [consultado 25/1/2017]. Disponible en: <http://gruposde-trabajo.sefh.es/farmacotecnia/images/stories/Boletines/BOLETIN32014final.pdf>
5. Dávila MC. Estabilidad, caducidad y conservación de Fórmulas Magistrales. En: Piñero Corrales G, coordinadora. *Aspectos prácticos de la farmacotecnia en un servicio de farmacia*. Madrid: Astellas Pharma; 2011; p. 133-48.
6. Atienza Fernández M, Martínez Atienza J. Formulación en Farmacia Pediátrica [página web en internet]. Madrid: Manuela Atienza; 2011 [2/5/2011, consultado 25/1/2017]. Disponible en: <http://formulacionpediatrica.es/procedimientos-pnt/>
7. Pharmaceutical Society of New Zealand incorporated. Standardised formulations for New Zealand [Base de datos en internet]. New Zealand: Chris Jay; 2010 [consultado 30/1/2017]. Disponible en: https://www.psnz.org.nz/Category?Action=View&Category_id=284
8. Nationwide Children's Hospital. Compounding Formulas [base de datos en internet]. Ohio: Nationwide Children's Hospital [consultado 30/1/2017]. Disponible en: <http://www.nationwidechildrens.org/outpatient-pharmacy-compounding-formulas>
9. Walsh K, Hook R. Sickkids [Base de datos en Internet]. Toronto: The Hospital for Sick Children; 1999 [2014; consultado 30/01/2017]. Disponible en: <http://www.sickkids.ca/pharmacy/compounding-service/index.html>
10. Arenz B. State-Wide initiative to standardize the compounding of oral liquids in Pediatrics. Michigan College [base de datos en internet]. Michigan; 2014 [2017; consultado 2/2/2017]. Disponible en: <http://www.mipedscompounds.org/about-initiative>
11. Sintas Ponte E, Vardulaki Operman A, Tarno Fernández ML, Núñez Velázquez A. *Formulario Nacional Español*. Madrid: Ministerio de Sanidad y Consumo, Secretaría General Técnica y Boletín Oficial del Estado; 2003.
12. Acofarma Distribución S.A. Fichas técnicas-Formulación Magistral [base de datos de internet]. Madrid: Carmen Bau; 2017 [consultado 29/1/2017]. Disponible en: <http://www.acofarma.com/es/formulacion-magistral/fichas-tecnicas>
13. Trissel LA. *Stability of Compounded Formulations*. 2.ª ed. Washington: American Pharmaceutical Association; 2000.
14. Jackson M, Lowey A. *Handbook of Extemporaneous Preparation, a guide to pharmaceutical compounding*. London: Pharmaceutical Press; 2010.
15. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de información online de medicamentos de la AEMPS [base de datos de internet]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad [consultado 29/01/2017]. Disponible en: <https://www.aemps.gob.es/cima/inicial.do>
16. Food and Drug Administration. *United States Pharmacopeia 32th edition and National Formulary. 27th edition*. Washington DC: Silver Spring; 2008.